Bone death from bisphosphonates covered in new litigation packet.
To advance AAJ members' knowledge about these drugs and help them assess, prepare, and litigate related products liability claims, the AAJ Exchange is offering a new litigation packet of information, "Fosamax, Zometa, and Other Bisphosphonates."
Millions of people, most of them postmenopausal women, have taken bisphosphonates to treat osteoporosis, low bone density, and metastasis of some cancers. Generally, the longer a person takes the medication, the greater their risk of complications such as osteonecrosis. Osteonecrosis of the jaw and the exposure of necrotic bone that accompanies it are irreversible conditions.
The litigation packet, developed with the help of AAJ members, summarizes emerging litigation concerning the link between osteonecrosis of the jaw and the use of Fosamax and Zometa. It includes a sample client questionnaire, a sample Zometa complaint, a time line of key events and studies, FDA preemption resources, contact information for AAJ plaintiff members investigating bisphosphohate cases, a bibliography of medical journals, Internet resources, and medical illustrations.
For more information on this and other Exchange litigation packets, visit www.justice.org/exchange and click on "Litigation Packets" or call the Exchange at (800) 344-3023.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||The Exchange|
|Date:||Jun 1, 2007|
|Previous Article:||New seminar explores rules of the road.|
|Next Article:||Baylor students are winners in trial advocacy competition.|